Biocon Q2 FY27 Earnings Call: Maintains 25% Ex-R&D Margin Guidance, $400 Mn 10-Year Brazil Deal

Biocon Ltd held its Q2 FY27 earnings call on November 04, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Modest Headline Growth, Dampened by a One-Off Shipment Deferment

• Q2 FY27 operating revenues grew 2% YoY — biopharma up 5% YoY and services up 13% QoQ; EBITDA came in at Rs.865 crores with net profit before exceptionals at Rs.44 crores.
• H1 FY27 operating revenues of Rs.8,725 crores (+6% YoY) — EBITDA of Rs.1,767 crores, with consolidated EBITDA margin at 20%.
• ~5% of Q2 FY27 revenues were deferred — certain biosimilar shipments missed revenue recognition due to logistics issues (including the geopolitical situation); revenues were booked in October (Q3 FY27). Management characterised the quarter as an aberration.
• Interest costs down 12% YoY to Rs.240 crores — the P&L benefit has been running since Q3 FY26 and is expected to continue.
• Leadership transition announced — COO Rhonda Duffy retires in March 2027 with George Kaliviotis taking over from April 2027; Mukesh Rathi becomes CTO in January 2027; Joshua Salci now leads both biologics and generics in North America following Matthew Eric's departure.

9% H1 Growth, Double-Digit Ambition, and a Landmark Genentech Settlement

• Biosimilars Q2 FY27 revenue of Rs.2,809 crores — EBITDA of Rs.623 crores, R&D at 7% of revenues; H1 FY27 revenue grew 9% YoY with EBITDA margin at 24%. Q2 reported figures were dampened by the one-off deferral.
• Management targets double-digit biosimilars growth in FY 2026-2027 (INR terms) — building on double-digit annualised growth over the last couple of years; no absolute 12-month revenue scale-up figure was quantified.
• Currency benefit of ~6-8% within FY 2026-2027 reported INR numbers — CFO Kedar Upadhye rebutted the suggestion that implied 11-12% FY 2026-2027 growth is largely currency-driven, noting underlying performance is tracked in USD.
• Genentech global settlement for Pebrelizo (biosimilar pertuzumab) — secures earliest licensed launch dates: EU and UK from early calendar 2027 and US from Q3 calendar 2028, subject to regulatory approvals; a positive CHMP opinion was received in Q2 FY27.
• North America added over $100 million in new contracts — major payer wins covering a majority of the US population; Yesintek (ustekinumab) US market share reached 34% as of Q2 FY27, surpassing the originator; FDA approved the Yesintek single-dose pre-filled auto-injector.
• Europe momentum — multiple Q2 FY27 launches (ustekinumab auto-injector, denosumab, aflibercept) and ~20 tender awards across Italy, Spain, France and Denmark; the pertuzumab biosimilar became the first mAb biosimilar recommended under EMA's tailored clinical development approach.
• Emerging markets: 13 new product launches — across APAC, Latin America and AFMET CIS in Q2 FY27; a second insulin fill-finish line was commissioned in Malaysia, with EMA and UK MHRA approval received.

$400 Mn, 10-Year Brazil Contract Anchors Long-Dated Visibility

• Biocon Biologics awarded a 10-year, $400 million TCV contract — under the Brazilian government's Productive Development Partnership (PDP) program, in partnership with Bahia Pharma and BioNovis; the consortium received 100% allocation, providing access to Brazil's public healthcare market.
• Supplies begin Q4 FY27 — the full annual run rate will show in FY28 numbers; management framed the contract as stable, high-visibility revenue over the next 10 years with visibility beyond FY27.
• Pertuzumab Europe opportunity opens in Q4 FY 2026-2027 across 27 markets — the US opens in FY 2027-2028, allowing time for launch preparation and contracting; management framed the global settlement as a tiered negotiation setting up clear growth drivers from FY 2026-2027 onward.
• Brazil semaglutide extension — Biocon is working with Biome in Brazil on semaglutide, extending the partnership-led approach into the GLP-1 opportunity with potential local manufacturing.

25% Ex-R&D Guidance Maintained Despite Q2 Aberration

• Full-year ex-R&D EBITDA margin guidance of 25% maintained for FY 2026-2027 — management expects strong 2H FY 2026-2027 growth versus 1H, supported by inventory build-up and very high order visibility on aflibercept, aspart, ustekinumab and pertuzumab.
• QoQ ex-R&D margin compression attributed to unusually high sales spillovers — typically ~1% of sales but higher in Q2 FY27, affecting insulin and MAPS (not new products); the CFO called the quarter an aberration.
• Deferred EBITDA quantum of roughly US$20 million flows into Q3 FY27 — only shipping-related expenditure is deferred; analyst Rasmik Oza (Nine Rays EquiSearch LLP) estimated ~Rs.135 crore flowing to Q3 FY27 EBITDA, which the CFO confirmed.
• $10 million of crude-linked input headwinds in H1 FY27 — $5 million higher freight and $5 million higher solvents costs, sitting in combined biopharma margins (not generics alone); management expects good easing in both over the balance few quarters of FY 2026-2027.
• Biosimilars EBITDA margins guided to the mid-20s% range (period unspecified) — improving as revenue scale and operating leverage build.
• D&A step-up in Q2 FY27 reflects launch intangibles and Malaysia line two depreciation — the CFO expects no very large increase from H2 FY 2026-2027 onward, with launched products amortising over ~10-12 year useful lives.

Generics Turnaround Delivers; Syngene in Transition

• Generics Q2 FY27 revenue of Rs.774 crores with EBITDA of Rs.64 crores — vs Rs.7 crores EBITDA in Q2 FY26; margin of 8% vs 1%; H1 FY27 revenue +15% YoY with EBITDA of Rs.120 crores vs a Rs.28 crores loss in H1 FY26.
• Liraglutide growing as per plan in the US — management credited Joshua Salci's team for reliable GLP-1 execution as a fully integrated player, while several competing players started and then exited the liraglutide space.
• R&D strategy shift to harvesting — prioritised toward peptides, fermentation and complex formulations; future R&D spend to be commensurate with revenues (period unspecified).
• Syngene Q2 FY27 revenue of Rs.833 crores (+13% QoQ) — EBITDA of Rs.175 crores with margin at 20% vs 15% in Q1 FY27; H1 FY27 revenue of Rs.1,569 crores and EBITDA of Rs.291 crores.
• FY27 remains a transition year for Syngene — amid reduced demand from a large biologics client, with trajectory expected to improve as the year progresses.

Stronger H2 Expected; Insulin Scale-Up and Semaglutide Optionality

• Management expects H2 FY27 to be stronger than H1 — supported by biosimilars momentum, continued generics profitability improvement and progressive Syngene recovery; focus on margins, free cash flows, debt reduction and ROCE improvement.
• Chairperson Kiran Mazumdar-Shaw expects strong double-digit growth in dollar terms in H2 FY 2026-2027 — translating into higher rupee-reported numbers only if the rupee remains at current levels or depreciates further.
• Insulin annual run-rate now exceeds $300 million — grown from sub-$100 million to $200-250 million and beyond; CEO Shreehas Tambe said demand is not a constraint ("just the innovators and us") and capacity additions continue; European supplies commenced in Q2 FY27, with the US opening "in a few quarters from now."
• No specific FY 2027-2028 commitment on commercial Aspart scale-up — a cautious, capacity-gated approach since Biocon cannot currently meet full Glargine demand; commercial Aspart entry will come "at some point" following capacity build-out.
• Interest should decline from Q3 FY 2026-2027 onward — the Rs.10-20 crore sequential increase in Q2 FY27 was partly currency and partly working-capital funding for new launches; ongoing run-rate cited at Rs.230-240 crore per quarter.
• Semaglutide fermentation edge — Biocon holds capability in both chemical synthesis and fermentation routes; fermentation "significantly reduces" drug substance/API cost for oral semaglutide, and management said "Yes, that is the expectation" on fermentation cost advantages driving share gains at launch, though no market-share target or timeline was quantified.
• Part D price erosion has become steeper than before — insulin pricing is stable given limited competition, but as competition heats up in Part B, margins will be pressured more than before.